International journal of hematology
Safety and effectiveness of lisocabtagene maraleucel following PD-1 blockade in relapsed or refractory PMBCL.
Kohei Yamaguchi, Takuji Yamauchi, Seiya Hirakawa, Hidetaka Nakagaki, Hakuei Nishihara, Masatoshi Shimo, Kensuke Sasaki, Teppei Sakoda, Fumiaki Jinnouchi, Kohta Miyawaki, Takahiro Shima, Yoshikane Kikushige, Yasuo Mori, Koichi Akashi, Koji Kato
Published: 202610.1007/s12185-025-04148-0
Abstract
Primary mediastinal B-cell lymphoma (PMBCL) is a distinct subtype of large B-cell lymphoma characterized by 9p24.1 copy-number alterations and PD-1-mediated immune evasion. This profile confers high sensitivity to PD-1 inhibitors such as pembrolizuma…
Preview only. Read the full abstract at the source